April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Post-hoc Analysis Of Pre-trial Medications Effect On IOP Lowering Response Of Two Topical Prostaglandins
Author Affiliations & Notes
  • Carlo E. Traverso
    Clinica Oculistica - Di NOG, University of Genova, Genova, Italy
  • Marina Papadia
    Clinica Oculistica - Di NOG, University of Genova, Genova, Italy
  • Alessandro Bagnis
    Clinica Oculistica - Di NOG, University of Genova, Genova, Italy
  • Riccardo Scotto
    Clinica Oculistica - Di NOG, University of Genova, Genova, Italy
  • Auli M. Ropo
    Clinical Rsrch & Med Affairs, Santen Oy, Helsinki, Finland
  • Hannu M. Uusitalo
    Department of Ophthalmology, University of Tampere, Tampere, Finland
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 233. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Carlo E. Traverso, Marina Papadia, Alessandro Bagnis, Riccardo Scotto, Auli M. Ropo, Hannu M. Uusitalo; Post-hoc Analysis Of Pre-trial Medications Effect On IOP Lowering Response Of Two Topical Prostaglandins. Invest. Ophthalmol. Vis. Sci. 2011;52(14):233.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate efficacy of tafluprost 0.0015% vs latanoprost 0.005% in relation to prior medication.

Methods: : Prospective randomized evaluation; pooled data from the two centers participating to the trial.

Results: : Sixty-seven patients enrolled: 22 were on PGs, 15 on other glaucoma medications and 30 naïve to therapy. 48 (72 %) had a positive outcome defined as a reduction in IOP of ≥25% . Prior PG users responded more frequently than those with no prior medication (OR 1.71 - not statistically significant). The difference between prior PG and other glaucoma medication users was smaller (OR 1.20). PG users responded (≥25% reduction of IOP) to a similar extent with latanoprost (8/11 patients ) and tafluprost (9/11 patients).

Conclusions: : Medical treatment trials often include a wash-out at the initiation of the study. Often patients are recruited irrelevant of prior medical regimen. Although differences in prior treatment did not show statistically significant differences in the results of latanoprost vs tafluprost in our study, the trend of IOP response in patients with prior PG treatment warrants further investigation, which could be useful in the interpretation of data and recommendations for subjects recruitment.

Keywords: clinical (human) or epidemiologic studies: biostatistics/epidemiology methodology • clinical (human) or epidemiologic studies: outcomes/complications • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×